Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Veligrotug · 2 trials · 1 indication
Proptosis Responder Rate in the most proptotic eye (i.e., reduction of proptosis of ≥ 2 mm from baseline \[without a corresponding increase of ≥ 2 mm in the other eye\]) as measured by exophthalmometer
| Arm | Type | Description |
|---|---|---|
| Veligrotug 10 mg/kg | EXPERIMENTAL | 5 infusions of Veligrotug 10 mg/kg |
| Veligrotug (VRDN-001)10 mg/kg | EXPERIMENTAL | Drug: 5 IV Infusions of veligrotug (VRDN-001)10 mg/kg |
| Placebo Drug | EXPERIMENTAL | Placebo Drug: 5 IV Infusions of placebo |
| Name | Type | Description |
|---|---|---|
| Veligrotug | DRUG | Veligrotug 10 mg/kg (5 infusions of Veligrotug 10 mg/kg) |
| Veligrotug (VRDN-001) | DRUG | Veligrotug (VRDN-001) is a humanized monoclonal antibody directed against the IGF-1 receptor |
| Placebo | DRUG | 5 IV infusions of placebo |
Key Inclusion Criteria: 1. Be able to understand the study procedures and the risks involved and be willing to provide written informed consent before the first study-related activity 2. Have completed at least 5 IV infusions and assessments required to determine proptosis responder status 3 weeks ...